Art. -Nr.: HY-100493

BP-1-102

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.26%
CAS. Nr.: 1334493-07-0
Formel: C₂₉H₂₇F₅N₂O₆S
Molecular Weight:626.59

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BP-1-102 Chemical Structure

CAS. Nr.: 1334493-07-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

IC₅₀ & Target^[1]

STAT3

6.8 μM (IC₅₀)

Alle STAT Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	4.17 μM Compound: 1d; BP-1-102	Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay	[PMID: 35476936]
143B	IC₅₀	4.4 μM Compound: 1d; BP-1-102	Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis	[PMID: 35476936]
143B	IC₅₀	5.87 μM Compound: 1d; BP-1-102	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
A549	IC₅₀	5 μM Compound: 3; SH4-54	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 34000483]
DU-145	EC₅₀	22.7 μM Compound: 17o	Cytotoxicity against human DU145 cells after 72 hrs by MTS assay Cytotoxicity against human DU145 cells after 72 hrs by MTS assay	[PMID: 21788134]
DU-145	IC₅₀	23 μM Compound: 9, BP-1-102	Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
HCT-116	IC₅₀	15.05 μM Compound: BP-1-102; 36	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29674294]
HOS	IC₅₀	6.44 μM Compound: 1d; BP-1-102	Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
JJN-3	EC₅₀	16.7 μM Compound: 17o	Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay	[PMID: 21788134]
MDA-MB-231	IC₅₀	2 μM Compound: 3; SH4-54	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 34000483]
MDA-MB-231	IC₅₀	6.8 μM Compound: 14; BP-1-102	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 28245116]
MDA-MB-468	EC₅₀	10.9 μM Compound: 17o	Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay	[PMID: 21788134]
MDA-MB-468	IC₅₀	11 μM Compound: 9, BP-1-102	Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
MG-63	IC₅₀	12.66 μM Compound: 1d; BP-1-102	Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
MGC-803	IC₅₀	5.6 μM Compound: 3; SH4-54	Antiproliferative activity against human MGC-803 cells Antiproliferative activity against human MGC-803 cells	[PMID: 34000483]
OCI-AML2	IC₅₀	10 μM Compound: 9, BP-1-102	Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
U2OS	IC₅₀	8.3 μM Compound: 14; BP-1-102	Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay	[PMID: 28245116]

In Vitro

BP-1-102 binds Stat3 with an affinity K_D of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro, with an IC₅₀ value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas^[2]. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1334493-07-0
Appearance Solid
Molecular Weight 626.59
Formel C₂₉H₂₇F₅N₂O₆S
Color White to off-white
SMILES

O=C(O)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(=O)(C4=C(F)C(F)=C(F)C(F)=C4F)=O)=O)C=C1O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (12)

All WB

Sort by:

Journal Impact Factor

Cell Metab

Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1. [Abstract]

2023 Oct 3;35(10):1688-1703.e10. PMID: 37793345
Nat Commun

IL6 supports long-term expansion of hepatocytes in vitro. [Abstract]

2022 Nov 29;13(1):7345. PMID: 36446858
Acta Pharm Sin B

Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification. [Abstract]

2025 Jan;15(1):409-423. PMID: 40041920
Cell Commun Signal

Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation. [Abstract]

2020 Jul 8;18(1):104. PMID: 32641132

BP-1-102 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2020 Jul 8;18(1):104. [Abstract]

Immunoblotting analysis of pulmonary STAT3 and pY-STAT3 in mice 24 h after CLP with BP-1-102 (BP) administration. BP downregulates the elevated pY-STAT3 level in the mouse lung 24 h after CLP.
Oncogene

Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. [Abstract]

2018 Nov;37(45):5952-5966. PMID: 29980788
Free Radic Biol Med

Zinc ions facilitate metabolic bioenergetic recovery post spinal cord injury by activating microglial mitophagy through the STAT3-FOXO3a-SOD2 pathway. [Abstract]

2025 Feb 1:227:64-79. PMID: 39613048
Int J Oncol

Abnormal expression of CDC25C in NSCLC is influenced by transcriptional and RNA N6‑methyladenosine‑mediated post‑transcriptional regulation. [Abstract]

2025 Apr;66(4):27. PMID: 39981934
Nanomedicine

Improving lipid nanoparticles delivery efficiency of macrophage cells by using immunomodulatory small molecules. [Abstract]

2025 Feb 3:64:102809. PMID: 39904398
Biochem Biophys Res Commun

BP-1-102 inhibits multiple pathways of NFATc1 activation to alleviate osteoporosis and downregulate osteoclast differentiation in ovariectomized mice. [Abstract]

2026 May 26. PMID: 42308767
Exp Ther Med

BP‑1‑102 exerts antitumor effects on T‑cell acute lymphoblastic leukemia cells by suppressing the JAK2/STAT3/c‑Myc signaling pathway. [Abstract]

2023 Mar 15;25(5):191. PMID: 37020528
Biomed Pharmacother

De novo interleukin-10 production primed by Lactobacillus sakei CVL-001 amplifies the immunomodulatory abilities of mesenchymal stem cells to alleviate colitis. [Abstract]

2024 Dec 19:182:117745. PMID: 39705909
Harvard University

2024 May.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 33 mg/mL (52.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5959 mL

7.9797 mL

15.9594 mL

5 mM

0.3192 mL

1.5959 mL

3.1919 mL

10 mM

0.1596 mL

0.7980 mL

1.5959 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Proliferating cells in 6- or 96-well plates are treated once with 0-30 μM BP-1-102 for 24 h or with 10 μM BP-1-102 for up to 96 h. Viable cells are counted by trypan blue exclusion/phase-contrast microscopy or assessed by a cell proliferation kit^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: Athymic nude mice with established tumors are grouped and then given BP-1-102 (in 0.05% DMSO in water) at 1 or 3mg/kg (i.v.) every 2 or every 3 d or 3 mg/kg (oral gavage, 100 μL) every day for 15 or 20 d. Animals are monitored every day, and tumor sizes are measured with calipers and body weights are taken every 2 or 3 d. For each treatment group, the tumor volumes for each set of measurements are statistically analyzed in comparison with the control group using a paired T test^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang X, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8. [Content Brief]

[2]. De Simone V, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015 Jul;34(27):3493-503. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5959 mL	7.9797 mL	15.9594 mL	39.8985 mL
	5 mM	0.3192 mL	1.5959 mL	3.1919 mL	7.9797 mL
	10 mM	0.1596 mL	0.7980 mL	1.5959 mL	3.9898 mL
	15 mM	0.1064 mL	0.5320 mL	1.0640 mL	2.6599 mL
	20 mM	0.0798 mL	0.3990 mL	0.7980 mL	1.9949 mL
	25 mM	0.0638 mL	0.3192 mL	0.6384 mL	1.5959 mL
	30 mM	0.0532 mL	0.2660 mL	0.5320 mL	1.3299 mL
	40 mM	0.0399 mL	0.1995 mL	0.3990 mL	0.9975 mL
	50 mM	0.0319 mL	0.1596 mL	0.3192 mL	0.7980 mL

Keywords

BP-1-102

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BP-1-102

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) BP-1-102

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BP-1-102

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) BP-1-102

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BP-1-102 Related Classifications

HY-100493 Related Classifications